IGF-1 DES
Also called DES(1-3)IGF-1
No single human route established in this referenceAnimal / laboratory reference
Research reference
Animal / laboratory study
des(1–3)IGF-I diabetic-rat experiment
Continuous experimental infusions
7 days
Tomas et al., Biochemical Journal (1991) ↗When results may show
IGF-1 DES
Evidence gap- When change was measured
- Nitrogen retention and protein synthesis were measured. These are not human recovery or strength endpoints.
- When to assess
- 7 days
- Conditions and limitations
- Streptozotocin-induced diabetic rats. DES is not mecasermin or LR3. No human starter, near-muscle injection rule, cycle or measured onset is established.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 2hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Tomas et al., Biochemical Journal (1991)DES is not mecasermin or LR3. No human starter, near-muscle injection rule, cycle or measured onset is established.